Douglas George Johnson
Engineers at 61 Pl, Arvada, CO
License number
Colorado 21081
Issued Date
Nov 18, 1983
Renew Date
Nov 1, 2015
Expiration Date
Oct 31, 2017
Type
Professional Engineer
Address
Address
13478 W 61St Pl, Arvada, CO 80004
Professional information
Preparation And Use Of A Stable Formulation Of Allosteric Effector Compounds
US Patent:
2007021, Sep 13, 2007
Filed:
May 16, 2007
Appl. No.:
11/749610
Inventors:
Douglas Johnson - Arvada CO, US
Mark Doty - Grayslake IL, US
James Kipp - Wauconda IL, US
Mark Doty - Grayslake IL, US
James Kipp - Wauconda IL, US
Assignee:
ALLOS THERAPEUTICS, INC. - Westminster CO
International Classification:
A61K 31/205, A61B 5/055
US Classification:
424009300, 514555000
Abstract:
A pharmaceutical composition of 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methyl-propionic acid or its physiologically acceptable salts suitable for parenteral administration includes an aqueous formulation of 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methyl-propionic acid or its physiologically acceptable salt and a buffer to maintain the pH from about 6 to about 11. The composition in accordance with the invention reduces the amount of particulate matter that forms in solution after heat sterilization. The invention also includes a process for making a pharmaceutical composition of 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methyl-propionic acid or its physiologically acceptable salt that has a shelf life in excess of thirty days and is useful in parenteral administration.
Preparation And Use Of A Stable Formulation Of Allosteric Effector Compounds
US Patent:
2003023, Dec 18, 2003
Filed:
Apr 10, 2002
Appl. No.:
10/120848
Inventors:
Douglas Johnson - Arvada CO, US
Mark Doty - Grayslake IL, US
James Kipp - Wauconda IL, US
Mark Doty - Grayslake IL, US
James Kipp - Wauconda IL, US
International Classification:
A61K031/195, A61K009/14
US Classification:
514/567000
Abstract:
A pharmaceutical composition of 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methyl-propionic acid or its physiologically acceptable salts suitable for parenteral administration includes an aqueous formulation of 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methyl-propionic acid or its physiologically acceptable salt and a buffer to maintain the pH from about 6 to about 11. The composition in accordance with the invention reduces the amount of particulate matter that forms in solution after heat sterilization. The invention also includes a process for making a pharmaceutical composition of 2-[4-[2-[(3,5-dimethylphenyl)amino]-2-oxoethyl]phenoxy]-2-methyl-propionic acid or its physiologically acceptable salt that has a shelf life in excess of thirty days and is useful in parenteral administration.
Compositions Of Allosteric Hemoglobin Modifiers And Methods Of Making The Same
US Patent:
2007029, Dec 20, 2007
Filed:
Apr 22, 2005
Appl. No.:
10/598874
Inventors:
Al Quick - Aurora CO, US
Antonio Santos - Columbus NJ, US
Alexandre J.G. Carvalho - Lisboa, PT
Douglas Johnson - Arvada CO, US
Jeffrey Etter - Boulder CO, US
Chris Murray - Arlington MA, US
Antonio Santos - Columbus NJ, US
Alexandre J.G. Carvalho - Lisboa, PT
Douglas Johnson - Arvada CO, US
Jeffrey Etter - Boulder CO, US
Chris Murray - Arlington MA, US
Assignee:
ALLOS THERAPEUTICS, INC. - Westminster CO
International Classification:
C07C 233/01, C07C 231/00, G01N 30/00, C07C 233/00
US Classification:
562455000, 436161000
Abstract:
The present invention provides novel compositions of allosteric hemoglobin modifiers which are substantially free of impurities, specifically polymeric impurities. In one embodiment, the novel compositions contain an allosteric hemoglobin modifier compound and less than 100 ppm of the polymeric impurities generated during the preparation of this compound. Included in the present invention are novel methods for preparing allosteric hemoglobin modifiers that are substantially free of polymeric impurities. Also included in the present invention are improved methods for the purification of the product formed by the method of this invention. The novel methods of purification comprise extracting the crude composition with a water immiscible or partially immiscible solvent such as methylisobutyl ketone (MIBK) to lower amounts of impurities, specifically polymeric impurities. Also included are methods to reduce impurities by recrystallization of the crude synthesized product, followed by filtration of the recrystallized product. The present invention also includes the products made by the processes of the invention and methods for analyzing compositions comprised of these products.
Compositions Of Allosteric Hemoglobin Modifiers And Methods Of Making The Same
US Patent:
7847120, Dec 7, 2010
Filed:
Apr 22, 2005
Appl. No.:
11/112389
Inventors:
Al Quick - Aurora CO, US
Antonio M. Santos - Columbus NJ, US
Alexandre J G G Carvalho - Lisbon, PT
Douglas G. Johnson - Arvada CO, US
Jeffrey B. Etter - Boulder CO, US
Christopher Murray - Arlington MA, US
Antonio M. Santos - Columbus NJ, US
Alexandre J G G Carvalho - Lisbon, PT
Douglas G. Johnson - Arvada CO, US
Jeffrey B. Etter - Boulder CO, US
Christopher Murray - Arlington MA, US
Assignee:
Virginia Commonwealth University Intellectual Property Foundation - Richmond VA
International Classification:
C07C 229/00, C07C 65/03
US Classification:
562457, 562471
Abstract:
The present invention provides novel compositions of allosteric hemoglobin modifiers which are substantially free of impurities, specifically polymeric impurities. In one embodiment, the novel compositions contain an allosteric hemoglobin modifier compound and less than 100 ppm of the polymeric impurities generated during the preparation of this compound. Included in the present invention are novel methods for preparing allosteric hemoglobin modifiers that are substantially free of polymeric impurities. Also included in the present invention are improved methods for the purification of the product formed by the method of this invention. The novel methods of purification comprise extracting the crude composition with a water immiscible or partially immiscible solvent such as methylisobutyl ketone (MIBK) to lower amounts of impurities, specifically polymeric impurities. Also included are methods to reduce impurities by recrystallization of the crude synthesized product, followed by filtration of the recrystallized product. The present invention also includes the products made by the processes of the invention and methods for analyzing compositions comprised of these products.
Device For Using Patient Blood As Diluent In Administering Pharmaceuticals
US Patent:
2005014, Jul 7, 2005
Filed:
May 21, 2003
Appl. No.:
10/514783
Inventors:
Douglas Johnson - Arvada CO, US
International Classification:
A61M037/00, A61B019/00, A61M005/32
US Classification:
604403000, 604406000, 604416000, 604006150, 604006160
Abstract:
The subject invention comprises an apparatus and a method for administering a pharmaceutical to a patient by collecting the patient's blood in a collection chamber and adding the drug thereto, followed by re-infusing the blood admix to the patient. The administration may be carried out on a batch or continuous basis.
Methods And Compositions To Reduce Tissue Irritation In Parenteral Formulations
US Patent:
2008003, Feb 14, 2008
Filed:
Aug 2, 2005
Appl. No.:
11/573063
Inventors:
Douglas Johnson - Arvada CO, US
Assignee:
ALLOS THERAPEUTICS, INC. - Westminster CO
International Classification:
A61K 31/715
US Classification:
514058000
Abstract:
Compositions comprising a therapeutic compound and a dextin are disclosed, as well as processes for the preparation of the compositions. Also disclosed are methods using the compositions, including a method for reducing local irritation and resulting pain from an injection of a therapeutic compound by administering the composition.
Crystalline And Amorphous Forms Of Efaproxiral Sodium
US Patent:
2007029, Dec 27, 2007
Filed:
Apr 22, 2005
Appl. No.:
10/598854
Inventors:
Douglas Johnson - Arvada CO, US
Chris Murray - Arlington MA, US
Stephan Parent - West Lafayette IN, US
David Jonaitis - Lafayette IN, US
Chris Murray - Arlington MA, US
Stephan Parent - West Lafayette IN, US
David Jonaitis - Lafayette IN, US
Assignee:
ALLOS THERAPEUTICS, INC. - Westminster CO
International Classification:
A61K 31/196, A61P 11/00, A61P 43/00, A61P 9/02, A61P 9/10, C07C 63/00
US Classification:
514563000, 562405000
Abstract:
There are provided in accordance with the present invention crystalline forms A, B, C, F, G, I, J, P, and Q of efaproxiral sodium. Also provided is the amorphous form of efaproxiral sodium. Also provided are methods of forming the novel polymorphs and the amorphous form of efaproxiral sodium, therapeutic methods utilizing them and pharmaceutical dosage forms containing them.
Ready To Use Ketorolac Formulations
US Patent:
2012010, Apr 26, 2012
Filed:
Oct 21, 2011
Appl. No.:
13/278703
Inventors:
Joseph V. Pergolizzi - Naples FL, US
Alexander Mironov - Naples FL, US
Chad James Pickens - Bend OR, US
Douglas Giles Johnson - Arvada CO, US
Alexander Mironov - Naples FL, US
Chad James Pickens - Bend OR, US
Douglas Giles Johnson - Arvada CO, US
Assignee:
RTU PHARMACEUTICALS, LLC - Naples FL
International Classification:
A61K 31/407, A61P 29/00
US Classification:
514413
Abstract:
Disclosed in certain embodiments is a pharmaceutical composition for parenteral administration comprising: